These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 33246499)

  • 1. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial.
    Devos T; Geukens T; Schauwvlieghe A; Ariën KK; Barbezange C; Cleeren M; Compernolle V; Dauby N; Desmecht D; Grimaldi D; Lambrecht BN; Luyten A; Maes P; Moutschen M; Romano M; Seyler L; Nevessignsky MT; Vandenberghe K; van Griensven J; Verbeke G; Vlieghe E; Yombi JC; Liesenborghs L; Verhamme P; Meyfroidt G
    Trials; 2020 Nov; 21(1):981. PubMed ID: 33246499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.
    Soto A; Krapp F; Vargas A; Cabrejos L; Argumanis E; García PL; Altamirano K; Montes M; Chacón-Uscamaita PR; García PJ
    Trials; 2021 May; 22(1):342. PubMed ID: 34001174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
    Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
    Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct antivirals working against the novel coronavirus: azithromycin (DAWn-AZITHRO), a randomized, multicenter, open-label, adaptive, proof-of-concept clinical trial of new antivirals working against SARS-CoV-2-azithromycin trial.
    Gyselinck I; Liesenborghs L; Landeloos E; Belmans A; Verbeke G; Verhamme P; Vos R; Janssens W;
    Trials; 2021 Feb; 22(1):126. PubMed ID: 33563325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter randomized trial to assess the efficacy of CONvalescent plasma therapy in patients with Invasive COVID-19 and acute respiratory failure treated with mechanical ventilation: the CONFIDENT trial protocol.
    Misset B; Hoste E; Donneau AF; Grimaldi D; Meyfroidt G; Moutschen M; Compernolle V; Gothot A; Desmecht D; Garigliany M; Najdovski T; Laterre PF
    BMC Pulm Med; 2020 Dec; 20(1):317. PubMed ID: 33287790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial.
    Diago-Sempere E; Bueno JL; Sancho-López A; Rubio EM; Torres F; de Molina RM; Fernández-Cruz A; de Diego IS; Velasco-Iglesias A; Payares-Herrera C; Flecha IC; Avendaño-Solà C; Palomino RD; Ramos-Martínez A; Ruiz-Antorán B
    Trials; 2021 Jan; 22(1):70. PubMed ID: 33472681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Passive Immunity Trial for Our Nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults.
    Self WH; Stewart TG; Wheeler AP; El Atrouni W; Bistran-Hall AJ; Casey JD; Cataldo VD; Chappell JD; Cohn CS; Collins JB; Denison MR; de Wit M; Dixon SL; Duggal A; Edwards TL; Fontaine MJ; Ginde AA; Harkins MS; Harrington T; Harris ES; Hoda D; Ipe TS; Jaiswal SJ; Johnson NJ; Jones AE; Laguio-Vila M; Lindsell CJ; Mallada J; Mammen MJ; Metcalf RA; Middleton EA; Mucha S; O'Neal HR; Pannu SR; Pulley JM; Qiao X; Raval JS; Rhoads JP; Schrager H; Shanholtz C; Shapiro NI; Schrantz SJ; Thomsen I; Vermillion KK; Bernard GR; Rice TW;
    Trials; 2021 Mar; 22(1):221. PubMed ID: 33743799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Convalescent plasma transfusion therapy in severe COVID-19 patients- a safety, efficacy and dose response study: A structured summary of a study protocol of a phase II randomized controlled trial.
    Chowdhury FR; Hoque A; Chowdhury FUH; Amin MR; Rahim A; Rahman MM; Yasmin R; Amin MR; Miah MT; Kalam MA; Rahman MS
    Trials; 2020 Oct; 21(1):883. PubMed ID: 33106167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.
    RECOVERY Collaborative Group
    Lancet; 2021 May; 397(10289):2049-2059. PubMed ID: 34000257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
    Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
    Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Early transfusion of convalescent plasma in older patients with COVID-19 to prevent disease progression: A structured summary of a study protocol for a randomised controlled trial".
    Teofili L; Landolfi R; Cingolani A; Antinori A; Vecchiet J; Sanguinetti M; Gasbarrini A; Pasciuto T; Orlando N; Lamonica S
    Trials; 2020 Oct; 21(1):875. PubMed ID: 33092632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial.
    Bégin P; Callum J; Heddle NM; Cook R; Zeller MP; Tinmouth A; Fergusson DA; Cushing MM; Glesby MJ; Chassé M; Devine DV; Robitalle N; Bazin R; Shehata N; Finzi A; McGeer A; Scales DC; Schwartz L; Turgeon AF; Zarychanski R; Daneman N; Carl R; Amorim L; Gabe C; Ellis M; Sachais BS; Loftsgard KC; Jamula E; Carruthers J; Duncan J; Lucier K; Li N; Liu Y; Armali C; Kron A; Modi D; Auclair MC; Cerro S; Avram M; Arnold DM
    Trials; 2021 May; 22(1):323. PubMed ID: 33947446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial.
    Balcells ME; Rojas L; Le Corre N; Martínez-Valdebenito C; Ceballos ME; Ferrés M; Chang M; Vizcaya C; Mondaca S; Huete Á; Castro R; Sarmiento M; Villarroel L; Pizarro A; Ross P; Santander J; Lara B; Ferrada M; Vargas-Salas S; Beltrán-Pavez C; Soto-Rifo R; Valiente-Echeverría F; Caglevic C; Mahave M; Selman C; Gazitúa R; Briones JL; Villarroel-Espindola F; Balmaceda C; Espinoza MA; Pereira J; Nervi B
    PLoS Med; 2021 Mar; 18(3):e1003415. PubMed ID: 33657114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nebulised surfactant for the treatment of severe COVID-19 in adults (COV-Surf): A structured summary of a study protocol for a randomized controlled trial.
    Dushianthan A; Clark H; Madsen J; Mogg R; Matthews L; Berry L; de la Serna JB; Batchelor J; Brealey D; Hussell T; Porter J; Djukanovic R; Feelisch M; Postle A; Grocott MPW
    Trials; 2020 Dec; 21(1):1014. PubMed ID: 33302976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing COVID-19 Convalescent Plasma in Adults Hospitalized With COVID-19: A Blinded, Randomized, Placebo-Controlled Trial.
    Self WH; Wheeler AP; Stewart TG; Schrager H; Mallada J; Thomas CB; Cataldo VD; O'Neal HR; Shapiro NI; Higgins C; Ginde AA; Chauhan L; Johnson NJ; Henning DJ; Jaiswal SJ; Mammen MJ; Harris ES; Pannu SR; Laguio-Vila M; El Atrouni W; de Wit M; Hoda D; Cohn CS; McWilliams C; Shanholtz C; Jones AE; Raval JS; Mucha S; Ipe TS; Qiao X; Schrantz SJ; Shenoy A; Fremont RD; Brady EJ; Carnahan RH; Chappell JD; Crowe JE; Denison MR; Gilchuk P; Stevens LJ; Sutton RE; Thomsen I; Yoder SM; Bistran-Hall AJ; Casey JD; Lindsell CJ; Wang L; Pulley JM; Rhoads JP; Bernard GR; Rice TW;
    Chest; 2022 Nov; 162(5):982-994. PubMed ID: 35780813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
    Piechotta V; Iannizzi C; Chai KL; Valk SJ; Kimber C; Dorando E; Monsef I; Wood EM; Lamikanra AA; Roberts DJ; McQuilten Z; So-Osman C; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2021 May; 5(5):CD013600. PubMed ID: 34013969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.